Immunic, Inc. (Nasdaq: IMUX), a New York-based biotechnology company, announced on Wednesday that it has named Simona Skerjanec, M.Pharm, MBA as its new director.

Skerjanec has around three decades of experience in the United States and internationally. She has most recently served as senior vice president, global head Neuroscience and Rare Diseases at Roche. She has also served as Neuroimmunology Franchise head at Roche. She has also held roles of increasing responsibility in development and commercialisation at The Medicines Company, Eli Lilly, Pfizer and Johnson & Johnson. She also serves on the board of directors of Avidity Biosciences.

Duane Nash, MD, JD, MBA, chairman of the Immunic board of directors, said, 'We are thrilled to add someone of Simona's exceptional calibre and expertise to our board of directors. As the company approaches multiple late-stage readouts for vidofludimus calcium in MS over the next two years, we are determined to continue building a strong foundation for potential success. Earlier this month, we were delighted to bring on Jason Tardio, a former Novartis and Biogen executive with extensive MS drug commercialisation experience, as Immunic's new chief operating officer and president. Now with Simona's entry onto the board, we are proud to augment the company's growing strength with a board member with such exceptional global leadership experience and who previously led one of the most successful commercial launches in MS history. Simona's guidance will be invaluable.'